Perioperative Docetaxel, Oxaliplatin, Fluorouracil, and Leucovorin (FLOT) in Patients with Gastric or Esophagogastric Junction Adenocarcinoma; Real-Life Experience

Basit Öğe Kaydı
dc.contributor.authorYildiz, Fatih
dc.contributor.authorEraslan, Emrah
dc.contributor.authorIlhan, Aysegul
dc.contributor.authorDemir, Hacer
dc.contributor.authorDemir, Nazan
dc.contributor.authorErdur, Erkan
dc.contributor.authorYildirim, Ozgen Ahmet
dc.date.accessioned2024-04-24T17:24:48Z
dc.date.available2024-04-24T17:24:48Z
dc.date.issued2020
dc.departmentDicle Üniversitesien_US
dc.description.abstractIn patients with gastic cancer, five-year survival is poor in the locally advanced stage. Docetaxel, oxaliplatin, leucovorin, and 5-fluorouracil (FLOT) combination regimen has been shown to provide a survival advantage in the locally advanced stage. In this study, we aimed to evaluate the efficacy and tolerability of FLOT with real-life data in patients with locally advanced gastric/esophagogastric junction cancers. This retrospective study was conducted between June 2016 - March 2020 and included 106 patients' data from six centers in Turkey. Median age was 60 (33-82). Primary tumor localization was stomach in 76 (71.7%) patients. Seventy-six (71.7%) patients were operated after median 4 (1-8 cycles) cycles of preoperative FLOT. Pathological complete regression (pCR)was obtained in 10 (13.1%) of the operated patients. Median follow-up was 9.1 (1.4-45.7) months. One-year DFS was 63.2% and the two-year OS was 65.1%. Three (2.8%) patients had chemotherapy-related deaths. Due to chemotherapy-related toxicity and intoleration, 19 (17.9%) patients had dose reduction. The pCR obtained by FLOT appears higher than other regimens. This study is one of the rare mufticentric real-life data showing the efficacy and tolerability of the FLOT regimen in the perioperative treatment in GC and EJC.en_US
dc.identifier.doi10.4999/uhod.204238
dc.identifier.endpage161en_US
dc.identifier.issn1306-133X
dc.identifier.issue3en_US
dc.identifier.startpage155en_US
dc.identifier.urihttps://doi.org/10.4999/uhod.204238
dc.identifier.urihttps://hdl.handle.net/11468/19839
dc.identifier.volume30en_US
dc.identifier.wosWOS:000574549000006
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.language.isoenen_US
dc.publisherAkad Doktorlar Yayinevien_US
dc.relation.ispartofUhod-Uluslararasi Hematoloji-Onkoloji Dergisi
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectGastric Canceren_US
dc.subjectPerioperative Chemotherapyen_US
dc.subjectNeoadjuvant Chemotherapyen_US
dc.subjectFloten_US
dc.subjectLocally Advanced Gastric Canceren_US
dc.titlePerioperative Docetaxel, Oxaliplatin, Fluorouracil, and Leucovorin (FLOT) in Patients with Gastric or Esophagogastric Junction Adenocarcinoma; Real-Life Experienceen_US
dc.titlePerioperative Docetaxel, Oxaliplatin, Fluorouracil, and Leucovorin (FLOT) in Patients with Gastric or Esophagogastric Junction Adenocarcinoma; Real-Life Experience
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu